Compare GSK plc (GSK) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marvell Technology Inc — how do they compare? GSK plc trades at $52.64 (market cap $101.34B), while Marvell Technology Inc trades at $187.78 (market cap $181.05B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MRVL | |
|---|---|---|
Market Cap | $101.34B | $181.05B |
Sector | Health | Technology |
52-Week High | $61.18 | $316.43 |
52-Week Low | $36.20 | $62.31 |
Enterprise Value | $121.95B | $182.48B |
Dividend Yield | 3.49% | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Marvell Technology (MRVL) trades at $222.44, up 2.26% today, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum on moving averages but has consistently beaten earnings estimates in recent quarters. Despite posting a net loss in 2025, revenue growth and strong analyst buy ratings (82%) signal optimism around its AI infrastructure and custom chip business.
Outlook remains positive with a consensus price target of $275.68, though high valuation multiples and competitive pressures pose risks. The key catalyst is execution on projected 40% revenue growth in fiscal 2027, but investors should monitor debt levels and semiconductor cycle volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
